Category: BieGene

  • Novartis In-Licenses BieGene’s Tislelizumab to Expand its Oncology Portfolio

    Shots: BieGene to receive $650M as up front along with milestones and royalties and will retain rights to Tislelizumab in China and other countries Novartis to get the development & commercialization rights to tislelizumab in the US, Canada, Mexico, EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, & Japan. Additionally, the companies have identified multiple tislelizumab […]